Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors

  • End date
    Nov 21, 2023
  • participants needed
  • sponsor
    University Health Network, Toronto
Updated on 21 October 2022
kidney cancer
renal neoplasm


Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.

Condition Renal Tumor
Treatment Stereotactic Ablative Radiotherapy
Clinical Study IdentifierNCT03747133
SponsorUniversity Health Network, Toronto
Last Modified on21 October 2022


Yes No Not Sure

Inclusion Criteria

Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm
Histological or radiological diagnosis of renal tumor
Inoperable: High risk for surgery or declined surgery
ECOG performance status of 0-3

Exclusion Criteria

≥5 active metastases
Sysstemic therapy (except endocrine therapy) wthin 6 days prior to SABR
Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the involved kidney
Patients with end stage renal failure > 4(KDOQI guidelines)
Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuber Sclerosis
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note